Home » Stocks » ONCS

OncoSec Medical Incorporated (ONCS)

Stock Price: $4.02 USD -0.07 (-1.71%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $4.27 +0.25 (6.22%) May 7, 5:37 PM
Market Cap 154.16M
Revenue (ttm) n/a
Net Income (ttm) -42.79M
Shares Out 28.68M
EPS (ttm) -1.71
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $4.02
Previous Close $4.09
Change ($) -0.07
Change (%) -1.71%
Day's Open 4.15
Day's Range 4.02 - 4.31
Day's Volume 204,178
52-Week Range 1.51 - 8.16

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

PENNINGTON, N.J. and SAN DIEGO, April 15, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a biotechnology company focused on cytokine-based intratumoral imm...

3 weeks ago - PRNewsWire

PENNINGTON, N.J. and SAN DIEGO, April 14, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a biotechnology company focused on cytokine-based intratumoral imm...

3 weeks ago - PRNewsWire

PENNINGTON, N.J. and SAN DIEGO, March 25, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a biotechnology company focused on cytokine-based intratumoral can...

1 month ago - PRNewsWire

PENNINGTON, N.J. and SAN DIEGO, Feb. 18, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced the appointment of Bridget O'Keeffe, Ph.D., a biotec...

2 months ago - PRNewsWire

PENNINGTON, N.J. and SAN DIEGO, Jan. 27, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) today announced that it has dosed several subjects in its Phase 1 clinical trial of CORVax12, th...

3 months ago - PRNewsWire

PENNINGTON, N.J. and SAN DIEGO, Jan. 20, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a late-stage biotechnology company focused on designing, developing...

3 months ago - PRNewsWire

PENNINGTON, N.J. and SAN DIEGO, Nov. 24, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a late-stage biotechnology company developing intra-tumoral cancer ...

5 months ago - PRNewsWire

OncoSec has had very promising results in metastatic melanoma. It has also expanded its program in triple-negative breast cancer to now treat first-line patients.

5 months ago - Seeking Alpha

PENNINGTON, N.J. and SAN DIEGO, Nov. 9, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced new positive interim data from its KEYNOTE-695 regist...

5 months ago - PRNewsWire

PENNINGTON, N.J. and SAN DIEGO, Oct. 12, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late- stage intra-tumoral cancer immunotherapi...

6 months ago - PRNewsWire

SAN DIEGO and PENNINGTON, N.J., Aug. 16, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec") today announced that in connection with its previously announced of...

8 months ago - PRNewsWire

SAN DIEGO and PENNINGTON, N.J., Aug. 14, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec") today announced that it intends to offer and sell shares of its com...

8 months ago - PRNewsWire

PENNINGTON, N.J. and SAN DIEGO, May 14, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS), a company developing late-stage intratumoral cancer immunotherapies, announced today that its pa...

11 months ago - PRNewsWire

Markets soar on US-China trade talk optimism.

Other stocks mentioned: BBBY, PUMP, RARX
1 year ago - GuruFocus

OncoSec Medical announced that it has licensed a CAR-T product from Dana-Farber Cancer Institute, specifically from The Marasco Laboratory.

1 year ago - Seeking Alpha

OncoSec Medical (ONCS) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

1 year ago - Zacks Investment Research

About ONCS

OncoSec Medical Incorporated, a biotechnology company, focuses on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. The company's lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 (IL-12) for reversing the immunosuppressive microenvironment in the treated tumor. It is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in Phase IIb clinical trials (KEYNOTE-695) and adva... [Read more...]

Industry
Biotechnology
Founded
2008
CEO
Daniel O'Connor
Employees
42
Stock Exchange
NASDAQ
Ticker Symbol
ONCS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for ONCS stock is "Strong Buy." The 12-month stock price forecast is 9.75, which is an increase of 142.54% from the latest price.

Price Target
$9.75
(142.54% upside)
Analyst Consensus: Strong Buy